Scientific Research Committee


Prof Chua Nam Hai - Chairman

Professor Chua Nam Hai has a distinguished academic career beginning with his B.S. in Botany and Biochemistry from the University of Singapore in 1965 and his A.M. and Ph.D. from Harvard University in 1967 and 1969, respectively. He was a lecturer in biochemistry at the University of Singapore Medical School from 1969 to 1971. Professor Chua joined Rockefeller in 1971 as a Research Associate in Cell Biology, was named Assistant Professor in 1973, Associate Professor in 1977 and Professor in 1981. Since 1988, Professor Chua holds the position of the Andrew W. Mellon Professor and Head of Laboratory of Plant Molecular Biology at the Rockefeller University, New York City.

Professor Chua has served and continues to serve on advisory boards of governmental organizations, academic institutions and multinational companies in 16 countries. He was awarded Einstein Professorship of the Chinese Academy of Sciences in 2007. He is currently the Chairman of the Strategic Research Program Management Committee and a member of the Management Board of Temasek Life Sciences Laboratory (Singapore). Professor Chua also serves as a Corporate Advisor to Temasek Holdings. In this capacity, he advises Temasek Holdings on potential biotechnology investments globally

Dr Arup Basu

Dr Arup Basu is President and CTO at Tata Chemicals Limited, responsible for New Businesses, Technology and Innovation. His earlier roles have included Head of Corporate Strategy, Member of the BoD of Tata Chemicals Magadi in Kenya, Chief Operating Officer of the Indian Chemicals Business and Manufacturing Head at Haldia Works, West Bengal where Tata Chemicals manufactures its Phosphatic Chemicals and Fertilizers.

Arup joined Tata Chemicals from Accenture where he was responsible for business development and managing large-scale projects for clients in the industrial space.  Prior to Accenture, he worked in a variety of roles at Indian Aluminium Company and at Tata Motors. 

Arup holds a PhD in Composite Materials from UMIST, Manchester and a B.Eng. in Materials Science & Engineering from Imperial College, London.

He is active in industry associations (Past Chairman – Maharashtra State Council of the Confederation of Indian Industry (CII) and past Regional Chairman (West) of the Indian Chemical Council) and a member on CII’s National Committee on Technology and “Start-Up” Council respectively.

Dr. Teh Bin Tean

Dr. Teh Bin Tean obtained his MD (1992) from the University of Queensland, Australia and his PhD (1997) from the Karolinska Institute, Sweden. Following postdoctoral works in multiple endocrine neoplasia 1 at Karolinska Institute, Dr. Teh joined the Van Andel Research Institute (VARI) in 2000 as a Senior Scientific Investigator heading the Laboratory of Cancer Genetics. In 2007, Dr. Teh was appointed as the founding Director of the National Cancer Centre Singapore (NCCS)-VARI laboratory, which serves as a bridge between translational research and clinical medicine. In 2010 he received the STaR award and relocated to Singapore and is currently a full professor in CSCB. He served as the SingHealth Group Director for Translational Research from 2010-2012. His laboratory focuses on genomic studies of cancers common among Asian populations, using tools such as high-throughput genomic platforms and correlation studies with clinico-pathological information. In the last 3 years, his group, in close collaboration with other groups at DUKE-NUS and SingHealth, has made significant advances in bile duct cancer, T-cell lymphoma and kidney cancer. Most recently, his group has made seminal discovery of the molecular fingerprints of carcinogen related to herbal plants. He holds Adjunct Professorships at several universities worldwide including Baylor College of Medicine, USA, Nanjing University and Sun Yat-Sen University, China and the Karolinska Institute, Sweden. Dr. Teh has published extensively, with over 300 publications in high impact scientific journals. He has been member of various editorial boards for journals including Lancet Oncology, Cancer Research, Molecular Cancer Therapeutics, International Journal of Oncology, Journal of Clinical Endocrinology and Metabolism, Clinical Genitourinary Cancer, and the American Journal of Translational Research. 

© JOil (S) Pte. Ltd. All rights reserved